Clinical Neuropathology QUIZ #11
Published in Clinical Neuropathology Vol 41 nr.1 (January/February 2022). Based on papers and editorial of Clinical Neuropathology of the same issue. https://www.dustri.com/nc/journals-in-english/mag/clinical-neuropathology/vol/volume-41-2022/issue/januaryfebruary-10.html
Sign in to Google to save your progress. Learn more
1. Which of the following cells do not typically express TTF-1? *
1 point
2. Which of the following is or are possible presenting symptom(s) in patients affected by hypothalamic hamartoma? *
1 point
3. Which of the following statement regarding subependymal giant cell astrocytoma (SEGA) is not correct? *
1 point
4. Which of the following tumors is not associated with tuberous sclerosis? *
1 point
5. Which of the following genes is implicated in the pathogenesis of primary meningeal melanocytic neoplasms? *
1 point
6. Which of the following immunohistochemical stains is not likely positive in melanocytoma? *
1 point
7. Which of the following is a feature of cerebellar liponeurocytoma? *
1 point
8. Which immunohistochemical stain is most likely to give a false negative result regarding a mutation in comparison to next-generation sequencing (NGS) in gliomas? *
1 point
9. Of the follwing genes, which one is most frequently mutated in gliomas and mixed glioneuronal tumors diagnosed within the first year of life? *
1 point
10. Which of the following tumor types is least common within the first year of life? *
1 point
Submit
Clear form
This form was created inside of Euro-CNS. Report Abuse